Treatment of Immune Thrombocytopenic Purpura in Children
- 1 January 2005
- journal article
- review article
- Published by Springer Science and Business Media LLC in Pediatric Drugs
- Vol. 7 (5), 325-336
- https://doi.org/10.2165/00148581-200507050-00004
Abstract
Treatment of immune thrombocytopenic purpura (ITP), the most common bleeding disorder of childhood, is a controversial subject for most practitioners. Diagnosis and management of ITP has historically been based primarily on expert opinion rather than on evidence. Due to a paucity of carefully conducted clinical trials in children, the management of ITP varies widely, ranging from observation only, to aggressive management with intravenous immunoglobulin (IVIG), intravenous anti-D rhesus (Rh)0 immunoglobulin (IV RhIG), corticosteroids, and splenectomy. To address the controversies, the American Society of Hematology (ASH) and the British Society for Hematology (BSH) have developed ITP practice guidelines. These guidelines, based on expert opinion, differ in their recommendations for treatment. The ASH guidelines favor therapy based on a low platelet count, and the more current BSH guidelines recommend a more conservative ‘wait and watch’ approach. In addition to treating children with severe bleeding symptoms, there is a tendency (not evidence based) to treat early in order to prevent a life-threatening bleeding episode, including intracerebral hemorrhage. Corticosteroids are a highly effective therapy, inexpensive, and can usually increase the platelet count within hours to days. However, chronic or prolonged use is associated with toxicity. In the US, based on the knowledge of known toxicities of corticosteroids, as well as the efficacy of alternative treatments (IV RhIG, IVIG), many pediatricians prefer to treat with IVIG and IV RhIG, reserving corticosteroid treatment for serious bleeding or refractory disease. However, in the UK, for the most part, corticosteroids are used as first-line therapy in children with ITP. Splenectomy is rarely indicated in children except for those with life-threatening bleeding and chronic, severe ITP with impairment of quality of life. For children who develop chronic or refractory ITP, immunosuppressive drugs and/or chemotherapy agents may offer some promise. However, the long-term effects of these drugs in children are unknown and they should not be considered unless there is unequivocal evidence that the patient is refractory to IV RhIG, IVIG, and corticosteroids. To date, virtually all of the randomized clinical trials conducted in children with ITP have focused on platelet counts as the sole outcome measure. Only carefully designed, multicenter, randomized clinical trials comparing the effects of different treatment modalities in terms of bleeding, quality of life, adverse effects, and treatment-related costs will be able to address the controversies surrounding childhood ITP treatment and allow management of this condition to be based on scientific data rather than treatment philosophy.Keywords
This publication has 113 references indexed in Scilit:
- Role of splenectomy in immune (idiopathic) thrombocytopenic purpuraBlood Reviews, 2002
- Novel approaches to refractory immune thrombocytopenic purpuraBlood Reviews, 2002
- Acute immune (idiopathic) thrombocytopenic purpura in childhoodBlood Reviews, 2002
- Platelet and immune responses to oral cyclic dexamethasone therapy in childhood chronic immune thrombocytopenic purpuraThe Journal of Pediatrics, 1997
- Characterization of autoantibodies against the platelet glycoprotein antigens llb/llla in childhood idiopathic thrombocytopenia purpuraAmerican Journal of Hematology, 1995
- A prospective, randomized trial of high-dose intravenous immune globulin G therapy, oral prednisone therapy, and no therapy in childhood acute immune thrombocytopenic purpuraThe Journal of Pediatrics, 1993
- A multicenter study of the treatment of childhood chronic idiopathic thrombocytopenic purpura with anti-DThe Journal of Pediatrics, 1992
- Mechanisms of Response to Treatment in Autoimmune Thrombocytopenic PurpuraNew England Journal of Medicine, 1989
- Treatment of Refractory Immune Thrombocytopenic Purpura with an Anti-Fcγ-Receptor AntibodyNew England Journal of Medicine, 1986
- Transient Reversal of Thrombocytopenia in Idiopathic Thrombocytopenic Purpura by High-Dose Intravenous Gamma GlobulinNew England Journal of Medicine, 1982